2023 World Conference on Lung Cancer (Posters)-P2.09. Clinical Characteristics and Outcomes of Patients with EGFR-mutant Lung Cancer with Acquired BRAF Alterations

P2.09. Clinical Characteristics and Outcomes of Patients with EGFR-mutant Lung Cancer with Acquired BRAF Alterations - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the clinical characteristics and outcomes of patients with EGFR-mutant lung cancer who developed acquired BRAF alterations following treatment with EGFR TKIs. The researchers analyzed data from 28 patients with EGFR-mutant lung cancer who had acquired BRAF alterations. The results showed that the majority of patients had adenocarcinoma histology and de novo metastatic disease. The most common acquired BRAF alteration was BRAFV600E. The median overall survival after detection of acquired BRAFV600E was 10 months. The median time to treatment discontinuation with EGFR TKI and RAF/MEK inhibitors was 3.5 months. Combination therapy with EGFR TKI and RAF/MEK inhibitors was used in 15 patients, with osimertinib and trametinib being the most common combination. The most common treatment-related adverse events were rash, diarrhea, and mucositis. Dose reduction was required in more than half of the patients. No patients received single-agent BRAF/MEK inhibitors without EGFR TKI after developing acquired BRAF alteration. Some patients had treatment-related adverse events requiring permanent discontinuation of treatment. The study concluded that further exploration of drug combinations is needed to improve treatment tolerability for patients with EGFR-mutant lung cancer and acquired BRAF alterations.

Asset Subtitle

Jane Sui

Meta Tag

Speaker Jane Sui

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

EGFR-mutant lung cancer

acquired BRAF alterations

clinical characteristics

outcomes

adenocarcinoma histology

BRAFV600E

overall survival

treatment discontinuation

combination therapy

treatment-related adverse events